Modeling HSV-1 Latency in Human Sensory Neurons Derived from iPSCs

Study Background and Research Question

Herpes simplex virus 1 (HSV-1) is a ubiquitous neurotropic virus responsible for recurrent infections in humans, ranging from mild cold sores to severe neurological complications such as encephalitis. After primary lytic infection in epithelial tissues, HSV-1 establishes lifelong latency in peripheral sensory and autonomic neurons, with periodic reactivation leading to disease recurrence. Despite decades of research, mechanistic understanding of HSV-1 latency and reactivation in human neurons remains limited, due largely to the lack of scalable, human-relevant neuronal models. Most previous in vitro studies have relied on animal neurons, which may not fully recapitulate human-specific epigenetic and signaling features (Oh et al., 2025).

Key Innovation from the Reference Study

The reference study by Oh et al. introduces a breakthrough protocol for rapidly differentiating human inducible pluripotent stem cells (hiPSCs) into functional sensory neurons capable of supporting HSV-1 latency and reactivation. Unlike previous attempts, this approach yields excitable neurons expressing functional ion channels and enables the establishment of latent HSV-1 infection characterized by key molecular hallmarks: absence of infectious virus, silencing of lytic gene expression, robust expression of latency-associated transcripts (LAT), and heterochromatinization of the viral genome (Oh et al., 2025).

Methods and Experimental Design Insights

The authors employed a multi-stage differentiation protocol to convert hiPSCs into sensory neuron lineages. The resulting neurons were validated for excitability and ion channel expression using electrophysiological assays, ensuring functional maturity. For viral studies, neurons were inoculated with HSV-1 under conditions optimized for latency establishment. Multiple readouts were used to distinguish latent from lytic infection states, including quantitative PCR for viral transcripts, immunofluorescence for protein markers, and chromatin immunoprecipitation for heterochromatin markers such as H3K9me3 and H3K27me3. Latency was further validated by the capacity of the system to support reactivation in response to known triggers (forskolin and PI3K inhibition), providing a dynamic model for both viral quiescence and recrudescence (Oh et al., 2025).

Protocol Parameters

• assay | human iPSC-derived sensory neuron differentiation | ~2 weeks | scalable production of excitable neurons for virological studies | paper
• assay | HSV-1 latency establishment | MOI and culture conditions as described | recapitulates key latency markers (LAT+, lytic−, heterochromatinized genome) | paper
• assay | HSV-1 reactivation | forskolin or PI3K inhibitor stimulation | triggers robust viral gene expression and reactivation | paper
• apoptosis assay | not directly reported in this study | possible application for assessing cellular responses to viral reactivation | workflow_recommendation
• cell cycle arrest | not the focus in this neuronal model | relevant in studies involving proliferating neural precursors or cancer models | workflow_recommendation

Core Findings and Why They Matter

The study demonstrates that hiPSC-derived sensory neurons can support all major molecular features of HSV-1 latent infection—lack of infectious virus production, suppression of lytic gene transcription, strong expression of LAT, and association of the viral genome with repressive histone modifications. Importantly, latent virus within these neurons can be efficiently reactivated using forskolin or PI3K inhibitors, recapitulating physiologically relevant triggers. This validates the system as a dynamic model for both latency and reactivation, overcoming the scalability and species-barrier limitations of primary human neuron cultures and animal models (Oh et al., 2025). The model paves the way for dissecting neuron-intrinsic mechanisms of HSV-1 persistence, chromatin regulation, and reactivation, and opens new avenues for screening therapeutic strategies targeting latent infection—a domain where current antiviral drugs are ineffective. The robust, scalable nature of this platform is especially valuable for the broader virology and neurobiology communities.

Comparison with Existing Internal Articles

While the primary focus of the Oh et al. study is on HSV-1 latency in human neurons, parallels can be drawn with research into receptor tyrosine kinase (RTK) signaling modulation in neural disease and oncology. Internal resources such as "SU 5402: Strategic Leverage of a Multi-Kinase Inhibitor for Disease Modeling" and "SU 5402: Precision FGFR3 Pathway Inhibition in Cancer & Neurobiology" discuss the use of small-molecule RTK inhibitors, including SU 5402, for probing signaling pathways implicated in both cancer biology and neuronal systems. Although SU 5402's primary literature base centers on cancer and myeloma models, mechanistic studies have shown its applicability in neural signal transduction, suggesting potential utility in models of neuronal infection where RTK pathways intersect with viral latency or reactivation (internal_article).

Why this cross-domain matters, maturity, and limitations

The intersection of RTK signaling, cell cycle regulation, and viral pathogenesis is an emerging area of interest. While direct evidence for SU 5402 or similar RTK inhibitors in HSV-1 latency models is currently lacking, related work in neuronal signaling and apoptosis assays provides a conceptual framework for investigating how host kinases might influence viral chromatin dynamics, latency maintenance, or reactivation. However, translation of findings from cancer and proliferative models to post-mitotic neurons requires careful experimental validation (internal_article; workflow_recommendation).

Limitations and Transferability

The hiPSC-derived sensory neuron system, while highly promising, is subject to limitations inherent to in vitro models. Notably, the microenvironmental cues present in vivo, including immune modulation and complex cell-cell interactions, are not fully recapitulated. Additionally, while the model supports robust latency and reactivation, the spectrum of neuronal subtypes and their relative susceptibility to infection may differ from native human ganglia. Transferability of findings to clinical settings will require complementary in vivo and ex vivo studies (Oh et al., 2025).

Research Support Resources

For researchers seeking to probe kinase-driven signaling pathways in neuronal or cancer models—including those studying the interface of RTK activity and viral latency—validated reagents such as SU 5402 (SKU A3843) from APExBIO offer precise, potent inhibition of VEGFR2, FGFR1, and PDGFRβ (source: product_spec). SU 5402 has been extensively used in multiple myeloma research, apoptosis assays, and cell cycle arrest studies to dissect the roles of RTKs in both oncogenic and neural contexts (internal_article). While not directly evaluated in the referenced HSV-1 latency model, SU 5402 may support analogous pathway interrogation in future studies involving neuronal infection and signaling cross-talk.